The price of Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) shares last traded on Wall Street fell -35.27% to $5.07.
MRVI stock price is now -37.34% away from the 50-day moving average and -37.47% away from the 200-day moving average. The market capitalization of the company currently stands at $828.64M.
On August 28, 2024, Wells Fargo recently initiated its ‘Overweight’ rating on the stock quoting a target price of $10, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’
In other news, GTCR INVESTMENT XI LLC, Director sold 9,940,974 shares of the company’s stock on May 28 ’24. The stock was sold for $97,570,660 at an average price of $9.81. Upon completion of the transaction, the Director now directly owns 20,150,005 shares in the company, valued at $102.16 million. A total of 17.53% of the company’s stock is owned by insiders.
During the past 12 months, Maravai LifeSciences Holdings Inc has had a low of $4.52 and a high of $11.56. As of last week, the company has a debt-to-equity ratio of 1.29, a current ratio of 10.00, and a quick ratio of 9.28. The fifty day moving average price for MRVI is $8.0995 and a two-hundred day moving average price translates $8.11615 for the stock.
The latest earnings results from Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) was released for 2024-09-30. The net profit margin was -81.13% and return on equity was -27.59% for MRVI. The company reported revenue of $73.4 million for the quarter, compared to $68.91 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.51 percent.
